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Abstract
Objective. To identify biomarkers of articular and ocular disease activity in patients with Blau syndrome (BS)
Methods. Multiplex plasma protein arrays were performed in five BS patients and eight normal healthy
volunteers (NHVs). Plasma S100A12 and S100A8/9 were subsequently measured by ELISA at baseline
and 1-year follow-up in all patients from a prospective multicentre cohort study. CRP was measured using
Meso Scale Discovery immunoassay. Active joint counts, standardization uveitis nomenclature for anterior
uveitis cells and vitreous haze by Nussenblatt scale were the clinical parameters.
Results. Multiplex Luminex arrays identified S100A12 as the most significantly elevated protein in five
selected BS vs eight NHVs and this was confirmed by ELISA on additional samples from the same five BS
patients. In the patient cohort, S100A12 (n=39) and S100A8/9 (n=33) were significantly higher compared
with NHVs (n=44 for S100A12, n=40 for S100A8/9) (P=0.0000004 and P=0.0003, respectively). Positive
correlations between active joint counts and S100 levels were significant for S100A12 (P=0.0008) and
S100A8/9 (P=0.015). CRP levels did not correlate with active joint count. Subgroup analysis showed
significant association of S100 proteins with active arthritis (S100A12 P=0.01, S100A8/9 P=0.008).
Active uveitis was not associated with increased S100 levels.
Conclusion. S100 proteins are biomarkers of articular disease activity in BS and potential outcome
measures in future clinical trials. As secreted neutrophil and macrophage products, S100 proteins may
reflect the burden of granulomatous tissue in BS.
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Rheumatology key messages
. This study identified S100A12 and S100A8/9 as biomarkers for articular disease activity in Blau syndrome.
. In Blau syndrome, S100 proteins showed a positive correlation with active joint count, whereas CRP did not.
Introduction
Blau syndrome (BS) is a dominantly inherited autoinflam-
matory disease resulting from mutations in or near the
nucleotide oligomerization domain of the gene encoding
nucleotide-binding oligomerization domain-containing
protein 2 (NOD2) [1]. A clinical triad of arthritis, dermatitis
and uveitis is characteristic, but involvement of various
organ systems has become recognized [24].
As a symmetrical polyarthritis with uveitis, BS resem-
bles polyarticular JIA, yet the synovitis in BS is more
exuberant than destructive and the uveitis affects both
compartments of the eye. Moreover, the presence of
non-caseating giant cell granulomas in affected tissues
reveals its distinct pathogenesis involving activated
macrophages as precursors of the characteristic multinu-
cleated cells [5]. To date, no biomarkers of disease activity
have been identified in BS.
Current management of BS involving corticosteroids,
DMARDs and biologic agents is less than satisfactory.
Despite multiple therapies, both articular and ocular
disease activity persists over time [6]. Specific drugs
targeting the NOD2 pathway are being sought and bio-
markers are likely to be required. S100A12, S100A8 and
S100A9, three phagocyte-specific S100 proteins compris-
ing the group of calgranulins, are secreted by activated
neutrophils and macrophages and have been proposed
as biomarkers in JIA [7, 8]. S100 proteins are candidates
for BS, a disease of activating and proliferating neutrophils
and macrophages.
One of the aims of our prospective BS cohort study is
the search for disease activity biomarkers. We will show
here that plasma levels of S100A12 and S100A8/9
proteins are associated with articular disease activity
and correlate positively with active joint counts in BS.
Methods
Patients and control subjects
BS patients with sequence-verified NOD2 mutations were
enrolled in the on-going BS multicentre prospective
cohort study involving 18 centers from 11 countries [6].
The age range for 39 BS patients included in this study
was 358 years (female/male: 18/21). Patients underwent
annual visits for clinical evaluation and sampling.
Measurement of active and limited joints was performed
by a rheumatologist using the 75-joint count score.
Patients underwent an ophthalmological evaluation
within a month of study visits. Standardization of Uveitis
Nomenclature classification was used to grade anterior
uveitis cells (range 04+). Vitritis was assessed by the
Nussenblatt scale (range 08). Blood samples were ob-
tained at baseline and at 1-year follow-up. Participation
in the biomarker studies was optional to centers and
participants. Normal healthy volunteers (NHVs) were re-
cruited from a pool of adults (age range: 2563 years;
female/male: 17/19) at GlaxoSmithKline (Collegeville, PA,
USA) and youth (age range: 522 years; female/male: 6/2)
from Leuven University Hospital (Leuven, Belgium). This
study was conducted in accordance with the ethical prin-
ciples of the Declaration of Helsinki and was approved by
the committee on Medical Ethics of the University
Hospitals KU Leuven and Ethics committees and
Institutional Review Boards at all clinical sites.
Sample collection
Blood was collected the same day of the clinical evalu-
ation. Corticosteroids were withheld for up to 24 h prior to
sampling when medically feasible. Additionally, all sam-
ples were collected as close to the nadir of any biologic
therapies as feasible. Peripheral blood was collected
following each study site’s approved venipuncture
procedure using standard methods for plasma isolation.
Plasma was stored in 1.5ml protein LoBind tubes
(Eppendorf) at 80C until further analysis. SF samples
were collected from both knees of a patient requiring
therapeutic arthrocentesis.
Plasma protein profiling and cytokine measurement
Plasma protein profiling was performed at Myriad RBM
(Austin, TX, USA) using the Human DiscoveryMAP 250+
multiplex Luminex array. The assay version used in these
studies measured 261 different cytokines and circulating
proteins. Plasma IL-8, IL-16 and CRP were measured
using Singleplex kits from Meso Scale Discovery
(Rockville, MD, USA). Plasma S100A12 was measured
using the CircuLex S100A12/EN-RAGE ELISA kit
(CycLex Co. Nagano, Japan). Plasma S100A8/9 heterodi-
mer was measured using Quantikine ELISA kit (R&D
Systems, Minneapolis, MN, USA).
Bioinformatic analysis
Plasma protein profiles were analysed using a partial least
squares discriminant analysis. Data was analysed using
JMP 11.0.0 software (SAS Institute, Cary, NC, USA).
Unpaired data endpoints that appeared to be approxi-
mately normal with similar variances were analysed
using a two-sample, two-sided t test to compare group
means, assuming unequal variances. Endpoints that vio-
lated the assumptions of normality and/or equal variance
were analysed using the non-parametric Wilcoxon rank-
sum test to compare groups.
Clinical assessment and analysis
Spearman’s rank test was used for correlations between
S100 proteins and CRP levels with joint counts.
Subgroups were stratified by articular and ocular disease.
Briefly a joint count = 0 was required for inactive arthritis,
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a standardization uveitis nomenclature grade of 0 for
inactive anterior uveitis and a Nussenblatt scale of 0
for inactive vitritis; the worse eye was considered when
involvement was asymmetrical. Inactive eye disease
required both inactive anterior uveitis and vitritis.
KruskalWallis and MannWhitney U tests were used for
comparisons of S100 and CRP levels between activity
groups.
Results
Significantly increased plasma S100A12 and
S100A8/9 in BS
To search for biomarkers of disease activity, we profiled
an agnostic set of 261 cytokines and circulating plasma
proteins from five BS patients and eight NHVs using
multiplex Luminex technology. Six proteins, S100A12,
IGFBP-3, IL-16, IL-8, PLGF and S100B, were more abun-
dant in BS with false discovery rate P< 0.1. Of those,
three proteins, IL-8, IL-16 and S100A12, represented
significant differences between BS and NHVs with false
discovery rate P< 0.015 (Fig. 1A). To confirm these
results, independent blood samples from these five BS
patients were collected 6 weeks after the initial blood
sampling and analysed using different immunoassays
(Singleplex kits from Meso Scale Discovery for IL-8 and
IL-16, ELISA for S100A12). The average levels of IL-8,
IL-16 and S100A12 were significantly increased in BS by
2.5-, 1.8- and 4.4-fold, respectively, relative to NHVs, con-
sistent with the initial Luminex results. Since S100A12
showed the highest increase in the five selected BS
patients vs eight NHVs, it became the focus of further
analysis.
Next, we measured plasma S100A12 in the whole cohort
of BS patients at baseline. The mean values of S100A12
[50.08 (34.01) ng/ml vs 20.08 (11.65) ng/ml, P=0.0000004]
were significantly increased in BS (n=39) compared with
NHVs (n=44) (Fig. 1B). Subsequently, we measured
plasma S100A8/9 heterocomplexes in the cohort of
patients at baseline because S100A8 and S100A9 have
already been shown to be biomarkers in JIA. The results
FIG. 1 S100A12 and S100A8/9 plasma levels in Blau syndrome
(A) Two hundred and sixty-one circulating proteins were examined in plasma from BS (n = 5) and NHV (n = 8) subjects using
multiplex Luminex arrays (left). Six differentially expressed plasma proteins with FDR P < 0.10; of those, IL-8, IL-16 and
S100A12 were significantly increased in BS relative to NHVs with FDR P< 0.015 (right). (B) Plasma levels of S100A12 in 39 BS
[50.08 (34.01) ng/ml] were significantly increased vs 44 NHVs [20.08 (11.65) ng/ml] with P = 0.0000004. (C) Plasma levels of
S100A8/9 heterodimer in 33 BS [1315 (886) ng/ml] were significantly increased vs 40 NHVs [730 (364) ng/ml] with P = 0.0003.
The data are shown as means (S.D.). BS: Blau syndrome; FDR: false discovery rate; NHV: normal healthy volunteer.
https://academic.oup.com/rheumatology 1301


















ZA user on 18 O
ctober 2019
showed significantly higher levels of S100A8/9 [1315
(886) ng/ml vs 730 (364) ng/ml, P=0.0003] in BS (n=33)
compared with NHVs (n=40) (Fig. 1C).
An additional observation was a robust elevation of
S100A12 and S100A8/9 in SF (patient 4, supplementary
Table S1, available at Rheumatology online). S100A12 and
S100A8/9 concentrations in SF were 154- and 27-fold,
respectively, higher than plasma concentrations obtained
the same day. A collection of SF from the right knee of the
same patient 2 year later confirmed the findings. Elevated
S100A12 and S100A8/9 concentrations in SF may reflect
local release from synovium into the joint space.
S100A12 and S100A8/9 correlate with articular
disease activity in BS
Clinical activity scores and NOD2 mutation data on 39 BS
patients are shown in supplementary Table S1, available at
Rheumatology online. Thirty-nine BS samples from the base-
line visit were available for S100A12 and CRP, and thirty-
three for S100A8/9 measurements. S100A12 and S100A8/9
values exhibited a positive correlation with active joint count
at baseline (R = 0.48/P=0.0008, R=0.42/P=0.015, respect-
ively) (Fig. 2A and B). At year 1, a positive correlation be-
tween S100A12 values and active joint count was confirmed
(R = 0.39/P=0.03). Plasma levels of CRP did not significantly
correlate with active joint count, although the mean values of
CRP [8.92 (13.52) mg/ml vs 2.73 (4.52) mg/ml] were higher in
BS (n=39) when compared with NHVs (n=40).
Higher S100A12 and S100A8/9 values in subgroups
of BS patients with active arthritis
Patients were then stratified in subgroups according to
presence or absence of active arthritis (A+, A) and
active uveitis (U+, U) based on the definitions described
in the methods both at baseline and at 1-year follow-up.
Four subgroups were identified at baseline: A+U+ (n=17),
A+U (n=10), AU+ (n=5) and AU (n=7). The median
(range) values for S100A12 in each group were 66
(21166), 38 (9104), 25 (1573) and 24 (950) ng/ml, re-
spectively. The KruskalWallis test showed a significant
difference among the four groups (P=0.02). Subgroup
analysis showed higher S100A12 values in patients with
active arthritis vs patients without, independent of uveitis
activity (P=0.01; Fig. 2C). S100A12 values in patients who
had both active arthritis and uveitis were not significantly
higher compared with values in patients with arthritis but
no uveitis, suggesting a predominant effect of articular
inflammation on S100A12 levels. For S100A8/9, median
(range) values in nanogram per millilitre were 1361
(5953611) for A+U+ patients (n=11), 1355 (8104434)
for A+U (n=9), 970 (4271686) for AU+ (n=6) and
731 (3341292) for AU (n=7). Subgroup analysis
FIG. 2 The correlation of plasma S100A12 and S100A8/9 levels with active joint counts in Blau syndrome
(A) Correlations between S100A12 (n = 39) and S100A8/9 (n = 33) levels with active joint counts at baseline in BS
(Spearman’s rank test). (B) S100A12 and S100A8/9 levels in BS with vs without active arthritis irrespective of uveitis
activity (MannWhitney U-test). All data are shown as medians and interquartile ranges. BS: Blau syndrome; A: arthritis;
U: uveitis; +: with active disease; : without active disease.
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revealed higher S100A8/9 values in patients with active
arthritis vs patients without, independent of uveitis activity
(P=0.008; Fig. 2D).
Discussion
We showed that S100A12 and S100A8/9 are associated
with active arthritis in BS. Further, plasma levels of
S100A12 and S100A8/9 correlate positively with the
number of active joints. Conversely, S100 protein levels
were not associated with active uveitis.
These findings suggest that the synovium is the major
contributor to circulating S100 protein levels in BS, which
is further supported by the prominently increased S100
levels in SF. The absence of association with uveitis
activity is different from what has been reported in JIA
and idiopathic uveitis [8]. This could be a consequence
of the few patients without arthritis in our cohort, hamper-
ing our ability to isolate the effect of uveitis. CRP levels did
not show association with articular disease activity, a fact
that matches the absence of overt systemic inflammatory
features in BS.
The S100A8/9 dimer (also known as calprotectin) and
S100A12 proteins are multifunctional secreted proteins
involved in cellcell signalling that promote myeloid pro-
liferation and modulation of the inflammatory response.
S100A12 and S100A8/9 are produced by activated
neutrophils and macrophages, and are chemotactic for
both [9]. Although the evidence in support of gain function
mutations of the NOD2 gene in BS is considerable [10],
ex vivo stimulation of NOD2 mutated peripheral blood
cells with muramyl dipeptide, its selective ligand, shows
an attenuated nuclear factor kB (NFkB)-dependent cyto-
kine response in supernatant [11, 12]. Correspondingly,
the phenotype of the majority of BS patients is character-
ized by inflammatory granulomatous organ involvement,
rather than overt systemic inflammation. Since S100A12
and S100A8/9 reflect the proliferation of activated neutro-
phils and macrophages in the inflamed hypertrophic
synovium, it was not surprising to find a strong correl-
ation with articular disease activity but not for CRP, a
hepatic product secreted upon systemic stimulation by
NFkB-dependent circulating cytokines.
We recognize a number of weaknesses in our study.
The fewer samples available at the year 1 visit may have
impaired our ability to confirm the differences between
clinical subgroups in S100 levels.
At this stage, S100 proteins may not be suitable for
monitoring disease activity in individual patients. Our cor-
relation analysis showed a lower performance of S100
proteins at the extreme values of joint counts. At present,
no composite clinical activity scores have been validated
for BS, and accordingly we used the active and limited
joint counts as clinical measures.
This is the first prospective study focused on biomarker
discovery for disease activity in BS. The design of our
study allowed us to obtain reliable clinical evaluations at
the time of blood sampling on a substantial number of
patients for this rare disease.
To conclude, we have successfully identified S100A12
and S100A8/9 as biomarkers for articular disease activity
in BS. Future efforts will include the search for an appro-
priate marker for uveitis activity as well as the collection of
more longitudinal data to confirm the efficiency of the
S100 biomarkers over time.
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